碳青霉烯
微生物学
革兰氏阴性菌
生物
克
感染控制
革兰氏阴性细菌感染
抗菌管理
细菌
临床微生物学
抗生素耐药性
医学
抗生素
重症监护医学
基因
遗传学
大肠杆菌
生物化学
作者
Patricia J. Simner,Johann Pitout,Tanis C. Dingle
摘要
SUMMARYThe carbapenems remain some of the most effective options available for treating patients with serious infections due to Gram-negative bacteria. Carbapenemases are enzymes that hydrolyze carbapenems and are the primary method driving carbapenem resistance globally. Detection of carbapenemases is required for patient management, the rapid implementation of infection prevention and control (IP&C) protocols, and for epidemiologic purposes. Therefore, clinical and public health microbiology laboratories must be able to detect and report carbapenemases among predominant Gram-negative organisms from both cultured isolates and direct from clinical specimens for treatment and surveillance purposes. There is not a "one size fits all" laboratory approach for the detection of bacteria with carbapenemases, and institutions need to determine what fits best with the goals of their antimicrobial stewardship and IP&C programs. Luckily, there are several options and approaches available for clinical laboratories to choose methods that best suits their individual needs. A laboratory approach to detect carbapenemases among bacterial isolates consists of two steps, namely a screening process (
科研通智能强力驱动
Strongly Powered by AbleSci AI